Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] ignore what was happening to my body. But denial only works for so long with FSHD. As I lost muscle strength, what replaced it was pain – pain in the […]
[…] lab. These changes can allow us to prove or disprove hypotheses about the cause of FSHD, and when done in stem cells, they might pave the way for a future […]
[…] Phase 1 clinical trial of losmapimod to treat the root cause of facioscapulohumeral dystrophy ( FSHD). Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed […]
[…] award for a project that will test stem cell therapy in a mouse model of FSHD. A second award goes to a new tactic to prevent DUX4 protein from setting […]
Today, The FSH Society, the world’s largest research-focused patient advocacy organization for facioscapulohumeral muscular dystrophy ( FSHD), announced that it has established its first-ever nationwide signature event, the Walk & Roll to […]
